17 February 2023
EMA/CVMP/46528/2023
Committee for Veterinary Medicinal Products

Summary of opinion[1] (post-authorisation)

Coxevac

Common name: *Coxiella burnetii* vaccine (inactivated)

On 15 February 2023, the Committee for Veterinary Medicinal Products (CVMP) adopted a positive opinion[2], recommending the granting of an extension to the terms of the marketing authorisation for the veterinary medicinal product Coxevac. The marketing authorisation holder for this veterinary medicinal product is CEVA Santé Animale.

Coxevac is currently authorised as suspension for injection for cattle and goats. The extension concerns the addition of sheep as a target species.

Detailed conditions for the use of this product are described in the summary of product characteristics (SPC) which will be published in the Union Product Database (UPD) and will be available in all official European Union languages after the marketing authorisation has been granted by the European Commission.

[1] Summaries of opinion are published without prejudice to the Commission Decision.
[2] Applicants may appeal any CVMP opinion, provided they notify the European Medicines Agency in writing of their intention to appeal within 15 days of receipt of the opinion.

Official address Domenico Scarlattilaan 6 ● 1083 HS Amsterdam ● The Netherlands
Address for visits and deliveries Refer to www.ema.europa.eu/how-to-find-us
Send us a question Go to www.ema.europa.eu/contact **Telephone** +31 (0)88 781 6000 An agency of the European Union